Advances in research on gut microbiota in elderly patients with chronic constipation

doi:10.3877/cma.j.issn.2095-8757.2023.04.007

Abstract

Abstract:

Chronic constipation is a common digestive disease among the elderly, and the recurrence and persistence of constipation symptoms can seriously affect the quality of life of the elderly and even induce other systemic diseases. Emerging evidence has highlighted a close relation between chronic constipation and intestinal flora disorders, and that an imbalance in the composition and diversity of intestinal flora will trigger or exacerbate chronic constipation symptoms. Due to aging and other factors, the intestinal flora of the elderly often has unique characteristics. This article discusses the changes of intestinal flora in elderly patients with chronic constipation, exploring the mechanisms of constipation in the elderly in terms of short-chain fatty acids, colonic transit time, and the brain-gut axis, as well as therapeutic options based on intestinal flora targets, such as probiotics, prebiotics, synbiotics, non-absorbable antibiotics, and fecal transplants, so as to provide theoretical basis and reference for the clinical treatment of elderly patients with chronic constipation.

Key words: Chronic constipation, Intestinal flora, Aged, Pathogenesis, Treatment

Kangwei Liu, Jianfeng Yao. Advances in research on gut microbiota in elderly patients with chronic constipation[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2023, 10(04): 40-46.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2023.04.007

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2023/V10/I04/40

References 66

[1]	中华医学会消化病学分会胃肠动力学组，中华医学会消化病学分会功能性胃肠病协作组.中国慢性便秘专家共识意见（2019，广州）[J].中华消化杂志，2019，39(9):577-598.
[2]	Mei Z, Xiao-Jiao Y, Hong-Ming Z, et al. Epidemiological study of elderly constipation in Beijing[J]. World J Gastroenterol, 2015, 21(47):13368-13373.
[3]	杨直，吴晨曦，高静，等.中国成年人慢性便秘患病率的Meta分析[J].中国全科医学，2021，24(16):2092-2097.
[4]	Chu H, Zhong L, Li H, et al. Epidemiology characteristics of constipation for general population, pediatric population, and elderly population in china[J]. Gastroenterol Res Pract, 2014, 2014:532734.
[5]	Du X, Liu S, Jia P, et al. Epidemiology of constipation in elderly people in parts of China: A multicenter study[J]. Front Public Health, 2022, 10:823987.
[6]	史佳强，郑松柏.老年人慢性便秘危害的研究进展[J].老年医学与保健，2022，28(5):1157-1160.
[7]	黄毕林，方中良，方向，等.老年慢性便秘患者营养和焦虑抑郁状态及认知功能分析[J].中国临床保健杂志，2022，25(2):190-194.
[8]	Aziz I, Whitehead WE, Palsson OS, et al. An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(1):39-46.
[9]	Palsson OS, Whitehead WE, van Tilburg MA, et al. Rome IV diagnostic questionnaires and tables for investigators and clinicians[J]. Gastroenterology, 2016:S0016-5085(16)00180-00183[pii].
[10]	Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography[J]. Nature, 2012, 486(7402):222-227.
[11]	Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body[J/OL]. PLoS Biol, 2016, 14(8):e1002533.
[12]	Schloissnig S, Arumugam M, Sunagawa S, et al. Genomic variation landscape of the human gut microbiome[J]. Nature, 2013, 493(7430):45-50.
[13]	Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome[J]. Nature, 2011, 473(7346):174-180.
[14]	Lv M, Zhang J, Deng J, et al. Analysis of the relationship between the gut microbiota enterotypes and colorectal adenoma[J]. Front Microbiol, 2023, 14:1097892.
[15]	周鲁宁，傅志良，尚庆森，等.一种基于肠道菌群肠型特征的膳食纤维组合物及其制备方法与应用：中国，CN115777949A[P].2023-03-14.
[16]	Mangiola F, Nicoletti A, Gasbarrini A, et al. Gut microbiota and aging[J]. Eur Rev Med Pharmacol Sci, 2018, 22(21):7404-7413.
[17]	Claesson MJ, Cusack S, O'Sullivan O, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly[J]. Proc Natl Acad Sci U S A, 2011,108(Suppl 1):4586-4591.
[18]	Ghosh TS, Das M, Jeffery IB, et al. Adjusting for age improves identification of gut microbiome alterations in multiple diseases[J/OL]. Elife, 2020, 9:e50240.
[19]	Biagi E, Franceschi C, Rampelli S, et al. Gut microbiota and extreme longevity[J]. Curr Biol, 2016, 26(11):1480-1485.
[20]	Arboleya S, Watkins C, Stanton C, et al. Gut bifidobacteria populations in human health and aging[J]. Front Microbiol, 2016, 7:1204.
[21]	余英.老年性便秘与肠道菌群失调的相关性及药物干预性研究[J].胃肠病学和肝病学杂志，2010，19(12):1133-1135.
[22]	Jocken JWE, González Hernández MA, Hoebers NTH, et al. Short-chain fatty acids differentially affect intracellular lipolysis in a human white adipocyte model[J]. Front Endocrinol (Lausanne), 2017, 8:372.
[23]	Agus A, Clément K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders[J]. Gut, 2021, 70(6):1174-1182.
[24]	Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity[J]. Nat Rev Immunol, 2016, 16(6):341-352.
[25]	Takiishi T, Fenero C, Câmara N. Intestinal barrier and gut microbiota: Shaping our immune responses throughout life[J]. Tissue Barriers, 2017, 5(4):e1373208.
[26]	Kamada N, Seo SU, Chen GY, et al. Role of the gut microbiota in immunity and inflammatory disease[J]. Nat Rev Immunol, 2013, 13(5):321-335.
[27]	Mousa WK, Athar B, Merwin NJ, et al. Antibiotics and specialized metabolites from the human microbiota[J]. Nat Prod Rep, 2017, 34(11):1302-1331.
[28]	Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis[J]. Cell, 2004, 118(2):229-241.
[29]	Stappenbeck TS, Hooper LV, Gordon JI. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells[J]. Proc Natl Acad Sci U S A, 2002, 99(24):15451-15455.
[30]	Cryan JF, O'Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis[J]. Physiol Rev, 2019, 99(4):1877-2013.
[31]	Martin CR, Osadchiy V, Kalani A, et al. The brain-gut-microbiome axis[J]. Cell Mol Gastroenterol Hepatol, 2018, 6(2):133-148.
[32]	Podlesny D, Fricke WF. Strain inheritance and neonatal gut microbiota development: A meta-analysis[J]. Int J Med Microbiol, 2021, 311(3):151483.
[33]	Ghosh TS, Rampelli S, Jeffery IB, et al. Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: The NU-AGE 1-year dietary intervention across five European countries[J]. Gut, 2020, 69(7):1218-1228.
[34]	Yuan G, Wen S, Zhong X, et al. Inulin alleviates offspring asthma by altering maternal intestinal microbiome composition to increase short-chain fatty acids[J/OL]. PLoS One, 2023, 18(4):e0283105.
[35]	郭航.拟杆菌和双歧杆菌对抗生素破坏后肠道菌群重建的影响[D].无锡：江南大学，2023.
[36]	黄林生，高仁元，严雪冰，等.慢性功能性便秘患者的肠道菌群分析[J/OL].中华结直肠疾病电子杂志，2017，6(2):121-126.
[37]	Guo M, Yao J, Yang F, et al. The composition of intestinal microbiota and its association with functional constipation of the elderly patients[J]. Future Microbiol, 2020, 15:163-175.
[38]	赵迪.基于代谢组学和肠道微生物组学的便秘与衰老的相关性研究[D].太原：山西大学，2021.
[39]	Tian H, Chen Q, Yang B, et al. Analysis of gut microbiome and metabolite characteristics in patients with slow transit constipation[J]. Dig Dis Sci, 2021, 66(9):3026-3035.
[40]	李菁，邹晓平，王钟晗，等.老年慢性便秘患者肠道菌群结构特点的研究[J].胃肠病学，2021，26(5):274-278.
[41]	Wang J, Wang L, Yu Q, et al. Characteristics of the gut microbiome and serum metabolome in patients with functional constipation[J]. Nutrients, 2023, 15(7):1779.
[42]	Yarullina DR, Shafigullin MU, Sakulin KA, et al. Characterization of gut contractility and microbiota in patients with severe chronic constipation[J/OL]. PLoS One, 2020, 15(7):e0235985.
[43]	Tan J, McKenzie C, Potamitis M, et al. The role of short-chain fatty acids in health and disease[J]. Adv Immunol, 2014, 121:91-119.
[44]	Huang XZ, Li ZR, Zhu LB, et al. Inhibition of p38 mitogen-activated protein kinase attenuates butyrate-induced intestinal barrier impairment in a Caco-2 cell monolayer model[J]. J Pediatr Gastroenterol Nutr, 2014, 59(2):264-269.
[45]	Calderon G, Patel C, Camilleri M, et al. Associations of habitual dietary intake with fecal short-chain fatty acids and bowel functions in irritable bowel syndrome[J]. J Clin Gastroenterol, 2022, 56(3):234-242.
[46]	Vieira-Silva S, Falony G, Darzi Y, et al. Species-function relationships shape ecological properties of the human gut microbiome[J]. Nat Microbiol, 2016, 1(8):16088.
[47]	Pimentel M, Lin HC, Enayati P, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity[J]. Am J Physiol Gastrointest Liver Physiol, 2006, 290(6):G1089-1095.
[48]	Suri J, Kataria R, Malik Z, et al. Elevated methane levels in small intestinal bacterial overgrowth suggests delayed small bowel and colonic transit[J/OL]. Medicine (Baltimore), 2018, 97(21):e10554.
[49]	Parkar N, Dalziel JE, Spencer NJ, et al. Slowed gastrointestinal transit is associated with an altered caecal microbiota in an aged rat model[J]. Front Cell Infect Microbiol, 2023, 13:1139152.
[50]	Liang J, Zhao Y, Xi Y, et al. Association between depression, anxiety symptoms and gut microbiota in Chinese elderly with functional constipation[J]. Nutrients, 2022, 14(23):5013.
[51]	Müller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation[J]. Aliment Pharmacol Ther, 2001, 15(10):1655-1666.
[52]	Kim CS, Cha L, Sim M, et al. Probiotic supplementation improves cognitive function and mood with changes in gut microbiota in community-dwelling older adults: A randomized, double-blind, placebo-controlled, multicenter trial[J]. J Gerontol A Biol Sci Med Sci, 2021, 76(1):32-40.
[53]	Zhang C, Jiang J, Tian F, et al. Meta-analysis of randomized controlled trials of the effects of probiotics on functional constipation in adults[J]. Clin Nutr, 2020, 39(10):2960-2969.
[54]	Takeda T, Asaoka D, Nojiri S, et al. Usefulness of bifidobacterium longum BB536 in elderly individuals with chronic constipation: A randomized controlled trial[J]. Am J Gastroenterol, 2023, 118(3):561-568.
[55]	Surakka Anu, Kajander K, Rajilic M, et al. Yoghurt containing galactooligosaccharides facilitates defecation among elderly subjects and selectively increases the number of Bifidobacteria[J]. Int J Prob Preb, 2009, 4(1):65-74.
[56]	Miyoshi M, Shiroto A, Kadoguchi H, et al. Prebiotics improved the defecation status via changes in the microbiota and short-chain fatty acids in hemodialysis patients[J]. Kobe J Med Sci, 2020, 66(1):E12-E21.
[57]	Lydia A, Indra TA, Rizka A, et al. The effects of synbiotics on indoxyl sulphate level, constipation, and quality of life associated with constipation in chronic haemodialysis patients: A randomized controlled trial[J]. BMC Nephrol, 2022, 23(1):259.
[58]	Oh JH, Jang YS, Kang D, et al. Efficacy of a synbiotic containing Lactobacillus paracasei DKGF1 and opuntia humifusa in elderly patients with irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial[J]. Gut Liver, 2023, 17(1):100-107.
[59]	Valentini Neto J, Chella TP, Rudnik DP, et al. Effects of synbiotic supplementation on gut functioning and systemic inflammation of community-dwelling elders - secondary analyses from a randomized clinical trial[J]. Arq Gastroenterol, 2020, 57(1):24-30.
[60]	Ghoshal UC, Srivastava D, Misra A. A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study[J]. Indian J Gastroenterol, 2018, 37(5):416-423.
[61]	Zeber-Lubecka N, Kulecka M, Ambrozkiewicz F, et al. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome[J]. Gut Microbes, 2016, 7(5):397-413.
[62]	Li H, Xiang Y, Zhu Z, et al. Rifaximin-mediated gut microbiota regulation modulates the function of microglia and protects against CUMS-induced depression-like behaviors in adolescent rat[J]. J Neuroinflammation, 2021, 18(1):254.
[63]	Kuai XY, Yao XH, Xu LJ, et al. Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation[J]. Microb Cell Fact, 2021, 20(1):98.
[64]	Ohara T. Identification of the microbial diversity after fecal microbiota transplantation therapy for chronic intractable constipation using 16s rRNA amplicon sequencing[J/OL]. PLoS One, 2019, 14(3):e0214085.
[65]	Fang S, Wu S, Ji L, et al. The combined therapy of fecal microbiota transplantation and laxatives for functional constipation in adults: A systematic review and meta-analysis of randomized controlled trials[J/OL]. Medicine (Baltimore), 2021, 100(14):e25390.
[66]	Saha S, Mara K, Pardi DS, et al. Long-term safety of fecal microbiota transplantation for recurrent Clostridioides difficile infection[J]. Gastroenterology, 2021, 160(6):1961-1969.e3.

Please choose a citation manager

Content to export